Enhanced NFκB and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer

Yamei Zhou, Christina Yau, Joe Gray, Karen Chew, Shanaz H. Dairkee, Dan H. Moore, Urs Eppenberger, Serenella Eppenberger-Castori, Christopher C. Benz

Research output: Contribution to journalArticle

135 Citations (Scopus)

Abstract

Background: Signaling pathways that converge on two different transcription factor complexes, NFκB and AP-1, have been identified in estrogen receptor (ER)-positive breast cancers resistant to the antiestrogen, tamoxifen. Methods: Two cell line models of tamoxifen-resistant ER-positive breast cancer, MCF7/HER2 and BT474, showing increased AP-1 and NFκB DNA-binding and transcriptional activities, were studied to compare tamoxifen effects on NFκB and AP-1 regulated reporter genes relative to tamoxifen-sensitive MCF7 cells. The model cell lines were treated with the IKK inhibitor parthenolide (PA) or the proteasome inhibitor bortezomib (PS341), alone and in combination with tamoxifen. Expression microarray data available from 54 UCSF node-negative ER-positive breast cancer cases with known clinical outcome were used to search for potential genes signifying upregulated NFκB and AP-1 transcriptional activity in association with tamoxifen resistance. The association of these genes with patient outcome was further evaluated using node-negative ER-positive breast cancer cases identified from three other published data sets (Rotterdam, n = 209; Amsterdam, n = 68; Basel, n = 108), each having different patient age and adjuvant tamoxifen treatment characteristics. Results: Doses of parthenolide and bortezomib capable of sensitizing the two endocrine resistant breast cancer models to tamoxifen were capable of suppressing NFκB and AP-1 regulated gene expression in combination with tamoxifen and also increased ER recruitment of the transcriptional co-repressor, NCoR. Transcript profiles from the UCSF breast cancer cases revealed three NFκB and AP-1 upregulated genes - cyclin D1, uPA and VEGF - capable of dichotomizing node-negative ER-positive cases into early and late relapsing subsets despite adjuvant tamoxfien therapy and most prognostic for younger age cases. Across the four independent sets of node-negative ER-positive breast cancer cases (UCSF, Rotterdam, Amsterdam, Basel), high expression of all three NFκB and AP-1 upregulated genes was associated with earliest metastatic relapse. Conclusion: Altogether, these findings implicate increased NFκB and AP-1 transcriptional responses with tamoxifen resistant breast cancer and early metastatic relapse, especially in younger patients. These findings also suggest that agents capable of preventing NFκB and AP-1 gene activation may prove useful in restoring the endocrine responsiveness of such high-risk ER-positive breast cancers.

Original languageEnglish (US)
Article number59
JournalBMC Cancer
Volume7
DOIs
StatePublished - 2007
Externally publishedYes

Fingerprint

Estrogen Receptor Modulators
Transcription Factor AP-1
Tamoxifen
Estrogen Receptors
Breast Neoplasms
bcl-1 Genes
Genes
Recurrence
Cell Line
Co-Repressor Proteins
Proteasome Inhibitors
MCF-7 Cells
Reporter Genes
Vascular Endothelial Growth Factor A
Transcriptional Activation
Transcription Factors
Gene Expression

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Enhanced NFκB and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. / Zhou, Yamei; Yau, Christina; Gray, Joe; Chew, Karen; Dairkee, Shanaz H.; Moore, Dan H.; Eppenberger, Urs; Eppenberger-Castori, Serenella; Benz, Christopher C.

In: BMC Cancer, Vol. 7, 59, 2007.

Research output: Contribution to journalArticle

Zhou, Y, Yau, C, Gray, J, Chew, K, Dairkee, SH, Moore, DH, Eppenberger, U, Eppenberger-Castori, S & Benz, CC 2007, 'Enhanced NFκB and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer', BMC Cancer, vol. 7, 59. https://doi.org/10.1186/1471-2407-7-59
Zhou, Yamei ; Yau, Christina ; Gray, Joe ; Chew, Karen ; Dairkee, Shanaz H. ; Moore, Dan H. ; Eppenberger, Urs ; Eppenberger-Castori, Serenella ; Benz, Christopher C. / Enhanced NFκB and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. In: BMC Cancer. 2007 ; Vol. 7.
@article{6ce68c9d67aa4b49ad539d601baffb2d,
title = "Enhanced NFκB and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer",
abstract = "Background: Signaling pathways that converge on two different transcription factor complexes, NFκB and AP-1, have been identified in estrogen receptor (ER)-positive breast cancers resistant to the antiestrogen, tamoxifen. Methods: Two cell line models of tamoxifen-resistant ER-positive breast cancer, MCF7/HER2 and BT474, showing increased AP-1 and NFκB DNA-binding and transcriptional activities, were studied to compare tamoxifen effects on NFκB and AP-1 regulated reporter genes relative to tamoxifen-sensitive MCF7 cells. The model cell lines were treated with the IKK inhibitor parthenolide (PA) or the proteasome inhibitor bortezomib (PS341), alone and in combination with tamoxifen. Expression microarray data available from 54 UCSF node-negative ER-positive breast cancer cases with known clinical outcome were used to search for potential genes signifying upregulated NFκB and AP-1 transcriptional activity in association with tamoxifen resistance. The association of these genes with patient outcome was further evaluated using node-negative ER-positive breast cancer cases identified from three other published data sets (Rotterdam, n = 209; Amsterdam, n = 68; Basel, n = 108), each having different patient age and adjuvant tamoxifen treatment characteristics. Results: Doses of parthenolide and bortezomib capable of sensitizing the two endocrine resistant breast cancer models to tamoxifen were capable of suppressing NFκB and AP-1 regulated gene expression in combination with tamoxifen and also increased ER recruitment of the transcriptional co-repressor, NCoR. Transcript profiles from the UCSF breast cancer cases revealed three NFκB and AP-1 upregulated genes - cyclin D1, uPA and VEGF - capable of dichotomizing node-negative ER-positive cases into early and late relapsing subsets despite adjuvant tamoxfien therapy and most prognostic for younger age cases. Across the four independent sets of node-negative ER-positive breast cancer cases (UCSF, Rotterdam, Amsterdam, Basel), high expression of all three NFκB and AP-1 upregulated genes was associated with earliest metastatic relapse. Conclusion: Altogether, these findings implicate increased NFκB and AP-1 transcriptional responses with tamoxifen resistant breast cancer and early metastatic relapse, especially in younger patients. These findings also suggest that agents capable of preventing NFκB and AP-1 gene activation may prove useful in restoring the endocrine responsiveness of such high-risk ER-positive breast cancers.",
author = "Yamei Zhou and Christina Yau and Joe Gray and Karen Chew and Dairkee, {Shanaz H.} and Moore, {Dan H.} and Urs Eppenberger and Serenella Eppenberger-Castori and Benz, {Christopher C.}",
year = "2007",
doi = "10.1186/1471-2407-7-59",
language = "English (US)",
volume = "7",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Enhanced NFκB and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer

AU - Zhou, Yamei

AU - Yau, Christina

AU - Gray, Joe

AU - Chew, Karen

AU - Dairkee, Shanaz H.

AU - Moore, Dan H.

AU - Eppenberger, Urs

AU - Eppenberger-Castori, Serenella

AU - Benz, Christopher C.

PY - 2007

Y1 - 2007

N2 - Background: Signaling pathways that converge on two different transcription factor complexes, NFκB and AP-1, have been identified in estrogen receptor (ER)-positive breast cancers resistant to the antiestrogen, tamoxifen. Methods: Two cell line models of tamoxifen-resistant ER-positive breast cancer, MCF7/HER2 and BT474, showing increased AP-1 and NFκB DNA-binding and transcriptional activities, were studied to compare tamoxifen effects on NFκB and AP-1 regulated reporter genes relative to tamoxifen-sensitive MCF7 cells. The model cell lines were treated with the IKK inhibitor parthenolide (PA) or the proteasome inhibitor bortezomib (PS341), alone and in combination with tamoxifen. Expression microarray data available from 54 UCSF node-negative ER-positive breast cancer cases with known clinical outcome were used to search for potential genes signifying upregulated NFκB and AP-1 transcriptional activity in association with tamoxifen resistance. The association of these genes with patient outcome was further evaluated using node-negative ER-positive breast cancer cases identified from three other published data sets (Rotterdam, n = 209; Amsterdam, n = 68; Basel, n = 108), each having different patient age and adjuvant tamoxifen treatment characteristics. Results: Doses of parthenolide and bortezomib capable of sensitizing the two endocrine resistant breast cancer models to tamoxifen were capable of suppressing NFκB and AP-1 regulated gene expression in combination with tamoxifen and also increased ER recruitment of the transcriptional co-repressor, NCoR. Transcript profiles from the UCSF breast cancer cases revealed three NFκB and AP-1 upregulated genes - cyclin D1, uPA and VEGF - capable of dichotomizing node-negative ER-positive cases into early and late relapsing subsets despite adjuvant tamoxfien therapy and most prognostic for younger age cases. Across the four independent sets of node-negative ER-positive breast cancer cases (UCSF, Rotterdam, Amsterdam, Basel), high expression of all three NFκB and AP-1 upregulated genes was associated with earliest metastatic relapse. Conclusion: Altogether, these findings implicate increased NFκB and AP-1 transcriptional responses with tamoxifen resistant breast cancer and early metastatic relapse, especially in younger patients. These findings also suggest that agents capable of preventing NFκB and AP-1 gene activation may prove useful in restoring the endocrine responsiveness of such high-risk ER-positive breast cancers.

AB - Background: Signaling pathways that converge on two different transcription factor complexes, NFκB and AP-1, have been identified in estrogen receptor (ER)-positive breast cancers resistant to the antiestrogen, tamoxifen. Methods: Two cell line models of tamoxifen-resistant ER-positive breast cancer, MCF7/HER2 and BT474, showing increased AP-1 and NFκB DNA-binding and transcriptional activities, were studied to compare tamoxifen effects on NFκB and AP-1 regulated reporter genes relative to tamoxifen-sensitive MCF7 cells. The model cell lines were treated with the IKK inhibitor parthenolide (PA) or the proteasome inhibitor bortezomib (PS341), alone and in combination with tamoxifen. Expression microarray data available from 54 UCSF node-negative ER-positive breast cancer cases with known clinical outcome were used to search for potential genes signifying upregulated NFκB and AP-1 transcriptional activity in association with tamoxifen resistance. The association of these genes with patient outcome was further evaluated using node-negative ER-positive breast cancer cases identified from three other published data sets (Rotterdam, n = 209; Amsterdam, n = 68; Basel, n = 108), each having different patient age and adjuvant tamoxifen treatment characteristics. Results: Doses of parthenolide and bortezomib capable of sensitizing the two endocrine resistant breast cancer models to tamoxifen were capable of suppressing NFκB and AP-1 regulated gene expression in combination with tamoxifen and also increased ER recruitment of the transcriptional co-repressor, NCoR. Transcript profiles from the UCSF breast cancer cases revealed three NFκB and AP-1 upregulated genes - cyclin D1, uPA and VEGF - capable of dichotomizing node-negative ER-positive cases into early and late relapsing subsets despite adjuvant tamoxfien therapy and most prognostic for younger age cases. Across the four independent sets of node-negative ER-positive breast cancer cases (UCSF, Rotterdam, Amsterdam, Basel), high expression of all three NFκB and AP-1 upregulated genes was associated with earliest metastatic relapse. Conclusion: Altogether, these findings implicate increased NFκB and AP-1 transcriptional responses with tamoxifen resistant breast cancer and early metastatic relapse, especially in younger patients. These findings also suggest that agents capable of preventing NFκB and AP-1 gene activation may prove useful in restoring the endocrine responsiveness of such high-risk ER-positive breast cancers.

UR - http://www.scopus.com/inward/record.url?scp=34247242607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247242607&partnerID=8YFLogxK

U2 - 10.1186/1471-2407-7-59

DO - 10.1186/1471-2407-7-59

M3 - Article

C2 - 17407600

AN - SCOPUS:34247242607

VL - 7

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

M1 - 59

ER -